Considering the mechanisms of action of these agents and the prominent involvement of IL-13 in CTCL pathogenesis, further exploration of their potential in CTCL treatment is warranted. The gene discussed is IL13; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.